New inhaled therapy targets lung scarring in early trial

NCT ID NCT05537025

Completed Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study tested an inhaled drug called ARO-MMP7 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The main goal was to check safety and how the body handles the drug. About 105 participants took part, receiving either the drug or a placebo via a nebulizer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARO-MMP7 inhalation solution
What this could lead to: If successful, this could point toward a new inhaled treatment to slow or control idiopathic pulmonary fibrosis, a serious lung-scarring disease.
What could go wrong: This is an early phase 1/2a trial focused on safety, so it is too soon to know if it works. The drug may cause side effects or fail to improve lung function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

Research Site 1

Copenhagen, DA-2100, Denmark
Research Site 1

Ancona, 60126, Italy
Research Site 1

Auckland, 1010, New Zealand
Research Site 1

Ulsan, 44033, South Korea
Research Site 1

Barcelona, 08017, Spain
Research Site 1

Birmingham, B15 2GW, United Kingdom
Research Site 2

Odense, DK-5000, Denmark
Research Site 2

Florence, 50134, Italy
Research Site 2

Christchurch, 08011, New Zealand
Research Site 2

Seoul, 05505, South Korea
Research Site 2

Oviedo, 33011, Spain
Research Site 2

Edinburgh, EH16 4SA, United Kingdom
Research Site 3

Milan, 20122, Italy
Research Site 3

Soeul, 21565, South Korea
Research Site 3

Santander, Cantabria, 39008, Spain
Research Site 3

Manchester, M8 5RB, United Kingdom
Research Site 4

Milan, 20122, Italy
Research Site 4

Manchester, M23 9QZ, United Kingdom
Research Site 5

Milan, 20123, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.